Real-world survival of patients treated with taxane therapy after exposure to immunotherapy and platinum-based chemotherapy for advanced non-small-cell lung cancer without actionable mutations
Background: The current therapy for advanced non-small-cell lung cancer (NSCLC) often incorporates frontline use of programmed death (ligand) 1 [PD-(L)1] inhibitors concomitantly or sequentially with platinum-based chemotherapy. For patients whose cancer then progresses, the impact of prior immunoth...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | ESMO Real World Data and Digital Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S294982012400002X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|